

**Company Contacts:
Nuvectra Corporation**

Walter Berger, COO & CFO
(214) 474-3102
wberger@nuvectramed.com

**Investor Contacts:
The Ruth Group**

Tram Bui / Brian Johnston
(646) 536-7035 / 7028
investors@nuvectramed.com

Nuvectra® to Participate in Two Upcoming Investor Conferences

Plano, Texas, October 31, 2018 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to participate in two upcoming investor conferences.

Event: 2018 Stephens NY Investment Conference
Date: Tuesday, November 6, 2018
Time: 9:00 a.m. ET
Location: Lotte New York Palace Hotel, New York
Format: Fireside Chat & 1x1 Meetings

Event: 30th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 28, 2018
Time: 11:30 a.m. ET
Location: Lotte New York Palace Hotel, New York
Format: Fireside Chat & 1x1 Meetings

Webcasts of the Company's fireside chats will be available by visiting the investor relations section of Nuvectra's website at www.nuvectramed.com. Webcast replays of the presentations will be available for 90 days.

About Nuvectra Corporation

Nuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson's Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.